Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube

Exploring Pragmatism of Lung Cancer Screening Randomized Controlled Trials Through a Primary Care Lens: Application of the PRECIS-2 Tool

ORIGINAL RESEARCH

Erin A. Hirsch, PhD; Jamie L. Studts, PhD; Susan Zane, MD, MPH; Marina McCreight, MPH; Amy G. Huebschmann, MD, MSc

Corresponding Author: Erin A. Hirsch, PhD; University of Colorado School of Medicine, Department of Medicine, Division of Medical Oncology

Email: Erin.Hirsch@cuanschutz.edu

DOI: 10.3122/jabfm.2024.240142R1

Keywords: Cancer Screening, Early Detection of Cancer, Implementation Science, Lung Cancer, Preventive Health, Primary Health Care

Dates: Submitted: 04-03-2024; Revised: 08-16-2024; Accepted: 08-26-2024

FINAL PUBLICATION: |HTML| |PDF|


OBJECTIVE: Lung cancer screening (LCS) implementation has been challenging for community and rural primary care settings. One contributing factor may be that the randomized clinical trials (RCTs) that form the evidence base are guided by explanatory methods not reflective of primary care settings. This study applied the PRagmatic Explanatory Continuum Indicator Summary (PRECIS – 2) tool to determine the pragmatism of LCS RCTs envisioned through a decentralized, primary care lens.

METHODS: LCS RCTs were identified from efficacy meta-analyses, and the VA Demonstration Project was chosen as a non-randomized multi-center comparator case. Two independent raters evaluated PRECIS-2 domains for each trial. Ratings were completed on a 5-point scale, where 1 indicated completely explanatory and 5 indicated completely pragmatic. Mean PRECIS-2 scores were calculated for each study and each domain. Descriptive information from raters’ comments was used to describe differences between the most pragmatic and most explanatory RCTs.

RESULTS: Eleven RCTs and the VA Demonstration Project were evaluated. Mean PRECIS-2 scores for each study ranged from 2.12 to 3.33, with the DLSCT rated the most explanatory and the Lung Screening Study and ITALUNG studies rated the most pragmatic. Six domains had a mean score <3, indicating more explanatory (eligibility, recruitment, setting, organization, staff flexibility, follow-up). The remaining three domains had mean scores >3, indicating more pragmatic (adherence, outcome, analysis).

DISCUSSION: This approach of evaluating each study from a primary care lens demonstrated that LCS RCTs trended toward a more explanatory nature, incorporating considerable support and infrastructure that extend beyond the capacity of typical primary care settings in the US. 

ABSTRACTS IN PRESS

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire